Introduction
MPV17-related mitochondrial DNA depletion syndrome (MPV17-MDS) is a rare, congenital, autosomal recessive primary mitochondrial disorder characterised by early-onset hepatopathy and neurologic manifestations. It is caused by pathogenic variants in the
MPV17 gene, which normally encodes a non-selective channel located in the inner mitochondrial membrane [
1‐
3]. Although the exact function of the
MPV17 channel remains unclear, its absence results in significant mitochondrial DNA (mtDNA) depletion, leading to an energy crisis in various cell types, most notably the liver.
MPV17-related mitochondrial DNA depletion syndrome accounts for the majority of nuclear DNA inherited mitochondrial disease known in Sub-Saharan Africa, due to the presence of a common pathogenic variant in
MPV17, namely c.106C>T [
4]. This variant has a predicted carrier frequency of one in 68 (95% CI 1 in 122 to 1 in 38) in the black South African population in the Western Cape and an estimated newborn incidence of one in 18,622 births (95%CI 1 in 59 to 1 in 5,776) in the same population [
5].
Presentation most often occurs during the neonatal period (38%) or infancy (58%), with a typical limited life span of only a few months [
2,
6]. Childhood onset has been reported in rare instances [
7]. Liver dysfunction occurs early, with neurological manifestations generally being mild at the onset of the disease [
8]. The clinical manifestations, in order of frequency, are liver dysfunction, liver failure, cholestasis, developmental delay, failure to thrive, hypotonia, microcephaly, lactic acidosis, hypoglycaemia and gastrointestinal dysmotility. Lesser common (<20%) manifestations include peripheral neuropathy, seizures, dystonia, ataxia, liver cirrhosis, renal tubulopathy, nephrocalcinosis, hypoparathyroidism, retinopathy and corneal ulcers. The prevalence of neuropathy may be underdiagnosed, as affected individuals often develop distal weakness only in later life. Bony changes associated with
MPV17 mutations include osteoporosis, osteopenia, scoliosis, platyspondyly and short stature [
3]. Life expectancy in cases with infantile onset (0–1 year) is usually less than 5 years, depending on age of onset, severity of symptoms and rate of disease progression.
Neuroimaging plays an important role in the investigation and management of patients with mitochondrial disorders, in some cases providing non-invasive and reproducible biomarker inquiry. The existing MRI literature on
MPV17-related mitochondrial DNA depletion syndrome is limited and lacks specificity. Radiological findings reported in case studies include white matter signal changes, abnormal myelination, and signal alterations in the brainstem and basal ganglia. Specific anatomical regions of the brain reportedly affected are non-unifying and include cerebellar white matter, middle cerebral peduncles, substantia nigra and dorsal brainstem [
9]. Notably, no study has identified a consistent or specific pattern of involvement, except for a case report on siblings and three children from Saudi Arabia, which showed nearly identical signal changes in the reticulospinal tracts and reticular formation on MRI [
10,
11].
This review aims to provide an overview of the genetic and clinical features of MPV17-related mitochondrial DNA depletion syndrome, accompanied by a detailed pictorial description of neuroimaging findings in eight affected infants, and a discussion of the key findings and their diagnostic implications.
Methods
This retrospective descriptive study was based at a large tertiary level hospital. Eight patients (five male) with genetically confirmed MPV17-related mitochondrial DNA depletion syndrome (encephalohepatopathy form) who underwent brain MRI were identified between 2015 and 2023. MRI was performed on a 1.5-T MAGNETOM Aera scanner (Siemens Healthineers, Erlangen, Germany). Six patients required general anaesthesia, and the other two were already intubated and ventilated. The standard MRI protocol included axial T1WI, axial and coronal T2WI, axial fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping, susceptibility-weighted imaging (SWI), and magnetisation-prepared rapid acquisition with gradient echo (MP-RAGE). Contrast was administered in five patients, although the specific indications for this are unknown. Magnetic resonance spectroscopy (MRS) was included in one protocol at the request of a clinician, using a short echo time (TE) of 30 ms with single-voxel acquisition. The neuroimaging findings were captured and described by specific anatomical site of involvement and signal abnormality. Two board-certified diagnostic radiologists with 8 years and 18 years of experience in adult and paediatric neuroradiology, respectively, reviewed all images by consensus. In addition to radiological data, demographic data, including patient age at diagnosis and MRI, sex, and clinical manifestations, were collected.
Results
Clinical presentation
All patients were homozygous for the MPV17: c.106C>T variant. The mean patient age at diagnosis was 10 weeks, with a range of 1 week to 32 weeks. The ages of the patients at the time of brain MRI ranged from 11 days to 32 weeks. There were no cases of familial consanguinity. All symptomatic infants presented with severe failure to thrive, characterised by weight, length and weight-for-height below the third percentile. Additional symptoms included cholestatic jaundice and gross motor delay. Physical examination findings consisted of central hypotonia (poor head control) with weakness (resulting in frog-like posture), reduced peripheral deep tendon reflexes and hepatomegaly, with or without splenomegaly. Microcephaly (head circumference below the third percentile for age and sex) was observed in two patients. Laboratory investigations revealed elevated transaminases and alkaline phosphatase, conjugated hyperbilirubinaemia, serum lactatemia and coagulopathy. Cerebrospinal fluid (CSF) lactate levels were assessed in all patients and found to be markedly elevated, exceeding 10 mmol/L. This is significantly higher than the normal reference range of 1.2–2.8 mmol/L. Cardiomyopathy, endocrinopathy, ophthalmological or bony abnormalities were not observed in any of the patients.
Neonatal manifestations included neonatal encephalopathy (n=3), characterised by lethargy and poor sucking, as well as neonatal seizures (n=2), jaundice and episodes of hypoglycaemia (n=3). One case presented with subtle seizures (lip-smacking), while the other exhibited tonic seizures. All patients were full-term babies with normal birth weights and unremarkable perinatal histories, except one patient who was preterm (32 weeks), human immunodeficiency virus (HIV) exposed but uninfected, with low birthweight for gestational age. The mother was on antiretroviral therapy, and the hyperlactatemia was initially attributed to this treatment. There was no relevant family history (early, unexplained deaths or miscarriages) in any of the families.
Out of the eight patients, five demised, two were lost to follow-up (status is unknown), and one child is still alive (age 62 weeks). The mean survival time was 39.6 weeks (range 5–70 weeks).
Discussion
The clinical manifestations evident in our cohort of eight children are like those described in the literature, with severe failure to thrive, cholestatic jaundice, and gross motor delay being the most frequent symptoms.
All patients in our cohort were homozygous for a severe
MPV17 pathogenic variant, expected to result in no functional protein. It is therefore possible that cases with milder presentations caused by variants that only reduce or alter the
MPV17 channel’s functionality, rather than result in absence of the channel, may present differently. This could explain the discrepancies in severity of the various clinical manifestations and the inconsistent imaging presentations documented in the existing literature [
9]. No information was available on the pathogenic variant affecting the siblings with reticular abnormalities described previously [
10].
To our knowledge, the only cases published in the
radiological literature are those of a sibling pair and three children from Saudi Arabia with variant-undisclosed
MPV17 who showed identical abnormalities of the reticulospinal tracts and reticular formation on 1.5-T MRI [
10]. Our findings strongly corroborated the hypothesis that this anatomical subsite is consistently affected in
MPV17-related mitochondrial DNA depletion syndrome patients, with seven out of eight of the patients in our series (and all encephalopathic patients) showing the same MRI abnormality.
The reticular formation is made up of a net-like structure of various brainstem nuclei and neurons and covers an expansive portion of the brainstem, beginning in the mesencephalon, extending caudally through the medulla oblongata, and projecting into the superior cervical spinal cord segments. The reticular formation does not have any distinct cytoarchitectural boundaries and is dispersed throughout the brainstem as a network of interconnected neurons with many projections cranially to subcortical and cortical brain structures as well as caudally to the spinal cord [
14]. The reticulospinal tract is a descending tract present in the white matter of the spinal cord, originating in the reticular formation. It consists of bundles of axons that carry information from the reticular formation in the brainstem to the peripheral body parts, being primarily responsible for locomotion and postural control [
15]. Since these structures reside at the craniocervical junction, which is located at the inferior edge of the field of view on standard brain MRIs, they may potentially be overlooked. For this reason, knowledge of this anatomical area and recognition of its relevance in
MPV17-related mitochondrial DNA depletion syndrome are essential in directing the imaging search. With higher magnetic field imaging at 3-T becoming increasingly available, it is expected that signal changes to the reticular formation should be more readily observed.
In addition to our study reinforcing the significance of the reticular formation and reticulospinal tracts in MPV17-related mitochondrial DNA depletion syndrome, it further characterises the topography, frequency, and extent of extra-reticular findings, including a predilection for the basal ganglia, a tendency to produce severe leukoencephalopathy, and frequent involvement of the corticospinal tracts. We establish that restricted diffusion occurs almost always at extra-reticular sites of involvement but infrequently in the reticular formation. Novel areas of interest, not previously described in the literature, are the perirolandic cortices and hippocampal formations, both regions of high mitochondrial activity, as well as the optic tracts and olfactory nerves.
These findings contribute to the scarce body of literature pertaining to the neuroimaging manifestations of
MPV17-related mitochondrial DNA depletion syndrome, despite the illness being largely defined by its neurological presentation. Since no specific patterns have been identified which would enable imaging to be used as a reliable diagnostic tool, these results establish a robust foundation to promote further exploration in this field [
6,
7,
10,
16].
In cases where the perirolandic cortices in neonates and hippocampi in older infants were affected, there was no history of asphyxia, signal changes were acute, as evidenced by restricted diffusion, and there were no accompanying basal ganglia or thalamic changes to suggest hypoxic ischemic injury.
For those patients with genetically confirmed MPV17-related mitochondrial DNA depletion syndrome in whom initial neuroimaging is normal, follow-up MRI would enhance our understanding of the natural history of the condition. However, it may not always be feasible due to the rapidly progressive trajectory of this form of the disease, subjecting patients to early demise (mean age of death approximately 10 months) or the development of complications that preclude general anaesthetic. None of the patients in our cohort underwent follow-up neuroimaging.
An additional consideration is that most patients with
MPV17-related mitochondrial DNA depletion syndrome present with cholestatic jaundice. It follows that hyperintense signal in the globus pallidi, identified in five of eight (62.5%) of the MRI studies, may indicate concurrent bilirubin encephalopathy, particularly in the two patients where the abnormality was linear and confined to the posteromedial aspects. The full diagnostic imaging triad of injury to the CA1 and CA2 sectors of the hippocampi and subthalamic nuclei was not, however, observed [
17].
Furthermore, since the administration of contrast did not result in pathologic enhancement in any cases, it is probably not indicated when strong clinico-radiological evidence exists for MPV17-related mitochondrial DNA depletion syndrome.
This study has two primary limitations. Firstly, we did not compare our findings to other mitochondrial disorders or different variants of
MPV17-related mitochondrial DNA depletion syndrome, which prevents us from determining the specificity of our results to
MPV17-related mitochondrial DNA depletion syndrome. Secondly, despite being the largest single-centre, single-variant cohort in the literature, our patient population is still relatively small, limiting the statistical significance of our findings. In contrast, the literature on better-known mitochondrial disorders like Leigh syndrome has identified characteristic imaging manifestations. Spongiform lesions of the basal ganglia (particularly the putamina) and brainstem, with a predilection for the midbrain and periaqueductal grey matter, are commonly observed. A study published in AJNR in 2000 analysed the MRI findings of eight patients with known Leigh syndrome and found that half had lesions conforming to the lower brainstem, reticular formation, or reticulospinal tracts. The authors proposed that the detection of lower brainstem lesions at the onset of respiratory abnormalities might be specific for Leigh syndrome [
18]. We now know that this is not the case and that such changes may be a manifestation of a broader range of mitochondrial conditions.
Conclusion
This review underscores the consistent presence of reticular lesions in neonates and infants with confirmed MPV17-related mitochondrial DNA depletion syndrome. The signal abnormality within the reticular formation and/or reticulospinal tracts may be a distinctive, albeit not specific, feature of the disorder. This highlights the importance of including the often-overlooked reticular formation in imaging evaluations of neonates or infants presenting with hepatic and neurological dysfunction.
Notably, reticular lesions may be apparent within days of birth in severe cases presenting with neonatal encephalopathy, hypotonia, and seizures. Familiarity with these imaging biomarkers can facilitate expedited diagnosis, particularly in resource-limited settings where genetic testing is unavailable or delayed. These findings warrant further exploration of imaging changes in other mitochondrial disorders, potentially leading to improved diagnostic accuracy and patient outcomes.
While this study primarily highlights the selective vulnerability of the reticular formation and reticulospinal tracts to MPV17-related mitochondrial DNA depletion syndrome, it also reveals additional important, less specific findings. These include a predilection for the basal ganglia, corticospinal, and other extra-reticular white matter tracts, a tendency to produce severe leukoencephalopathy, frequent restricted diffusion in the affected brain regions, and involvement of previously undescribed areas, including the perirolandic regions, hippocampal formations, optic tracts, and olfactory nerves. Notably, MRI contrast agents may not be necessary when strong clinico-radiological evidence supports MPV17-related mitochondrial DNA depletion syndrome.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.